TAMPA, FL - (BUSINESS WIRE) — January 13, 2005 — Nanobac Life Sciences, Inc. (OTCBB: NNBP) (“Nanobac” or “the Company”) informs that many cardiovascular researchers have shown that atherosclerosis might be the life-long result of our bodies’ various healing mechanisms and inflammatory responses to infection. A longstanding problem has been to isolate an infectious agent that is present in our tissues that could stimulate the development of atherosclerotic plaques. Until recently, no single infection, viral or bacterial, had been implicated.
Because of the significance and severity of atherosclerosis, and the Company’s belief that nanobacteria might play a key role in its development, Nanobac focused its early efforts on investigating the relationship between nanobacteria and atherosclerosis. This release is intended to summarize what has been determined thus far, and what remains to be done.
Three recently published studies conducted by prominent medical researchers have collectively shown that nanobacteria might be the previously unidentified agent involved in the development of atherosclerotic heart disease. A group of researchers at Mayo Clinic, led by Virginia Miller, PhD showed that nanobacteria are present in calcified atherosclerotic coronary arteries and heart valves.
In September 2004, cardiovascular researcher Benedict Maniscalco, MD published a study showing that patients with severe coronary artery heart disease tested positive for nanobacterial antigen. The study also indicates that a majority of cardiac patients that received, Tetracycline, EDTA (Nanobac Life Sciences, Tampa, FL) and a proprietary blend of nutritional supplements (Nanobac Life Sciences, Tampa, FL) had a decrease in their coronary artery calcium scores. His research group continues to evaluate effective nanobiotics in treating nanobacteria infections and their associated calcified plaques.
Finally, at a recent American Heart Association scientific session in New Orleans, one of the world’s most prominent heart disease researchers, Stephen E. Epstein, MD, Director of the Cardiovascular Research Institute at Washington Hospital Medical Center in DC, reported that 94% of people with calcified coronary arteries have nanobacterial infection as measured by Nanobac’s Nanobacterial Antibody Assay, and that antibody results correlated with coronary calcification scoring.
The collective weight of the three studies suggests that nanobacteria infection is arguably the previously unknown infectious agent associated with atherosclerotic plaque. Since nanobacteria are physically present in the diseased atherosclerotic tissues and are statistically correlated with heart disease calcification levels, it is also reasonable to assume that long term nanobacteria infection is involved in the development of the calcification in atherosclerotic heart disease.
Currently, atherosclerosis is a lifelong disease process that can lead to debilitating coronary artery heart disease, kidney disease, and many other chronic diseases. Early diagnosis and treatment of nanobacterial infections may ultimately lead to early recognition of heart disease.
The Company continues to research the relationship between nanobacterial infection and heart disease, and has expanded its research to include other diseases involving pathological calcification. The Company is seeking to collaborate, partner, or joint venture with other entities to further evaluate, test and commercialize both its diagnostic and therapeutic products and pipeline. The Company is in the process of identifying, negotiating, and concluding these relationships.
Nanobac Life Sciences, Inc. is dedicated to improving people’s health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company’s pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2™ ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.